Citadel Advisors’s aTyr Pharma ATYR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $741K | Buy |
1,242,067
+1,194,695
| +2,522% | +$780K | ﹤0.01% | 8927 |
|
|
2026
Q1 | $37K | Buy |
+47,372
| New | +$40K | ﹤0.01% | 12519 |
|
|
2025
Q3 | – | Sell |
-119,117
| Closed | -$540K | – | 14404 |
|
|
2025
Q2 | $604K | Sell |
119,117
-141,890
| -54% | -$558K | ﹤0.01% | 8184 |
|
|
2025
Q1 | $788K | Buy |
261,007
+248,646
| +2,012% | +$907K | ﹤0.01% | 7483 |
|
|
2024
Q4 | $44.7K | Sell |
12,361
-954,246
| -99% | -$2.89M | ﹤0.01% | 12502 |
|
|
2024
Q3 | $1.7M | Sell |
966,607
-878,655
| -48% | -$1.6M | ﹤0.01% | 5838 |
|
|
2024
Q2 | $2.88M | Sell |
1,845,262
-58,084
| -3% | -$101K | ﹤0.01% | 4634 |
|
|
2024
Q1 | $3.71M | Buy |
1,903,346
+149,746
| +9% | +$261K | ﹤0.01% | 4434 |
|
|
2023
Q4 | $2.47M | Sell |
1,753,600
-30,536
| -2% | -$39.2K | ﹤0.01% | 4993 |
|
|
2023
Q3 | $2.82M | Buy |
1,784,136
+1,464,046
| +457% | +$2.71M | ﹤0.01% | 4590 |
|
|
2023
Q2 | $691K | Buy |
320,090
+279,161
| +682% | +$609K | ﹤0.01% | 7229 |
|
|
2023
Q1 | $86K | Buy |
40,929
+3,092
| +8% | +$6.78K | ﹤0.01% | 11474 |
|
|
2022
Q4 | $82.9K | Buy |
+37,837
| New | +$89.2K | ﹤0.01% | 11478 |
|
|
2022
Q2 | – | Sell |
-159,921
| Closed | -$578K | – | 14295 |
|
|
2022
Q1 | $855K | Sell |
159,921
-33,573
| -17% | -$190K | ﹤0.01% | 8066 |
|
|
2021
Q4 | $1.45M | Sell |
193,494
-6,921
| -3% | -$57.8K | ﹤0.01% | 6976 |
|
|
2021
Q3 | $1.82M | Buy |
200,415
+170,542
| +571% | +$1.02M | ﹤0.01% | 6597 |
|
|
2021
Q2 | $145K | Buy |
29,873
+16,403
| +122% | +$69.9K | ﹤0.01% | 12536 |
|
|
2021
Q1 | $60K | Buy |
+13,470
| New | +$63.4K | ﹤0.01% | 12808 |
|
|
2020
Q3 | – | Sell |
-11,998
| Closed | -$53K | – | 10856 |
|
|
2020
Q2 | $53K | Sell |
11,998
-6,607
| -36% | -$24K | ﹤0.01% | 9279 |
|
|
2020
Q1 | $52K | Buy |
18,605
+4,831
| +35% | +$20.9K | ﹤0.01% | 9016 |
|
|
2019
Q4 | $57K | Buy |
+13,774
| New | +$53.2K | ﹤0.01% | 8722 |
|
|
2019
Q2 | – | Sell |
-5,782
| Closed | -$45K | – | 9971 |
|
|
2019
Q1 | $45K | Buy |
5,782
+3,534
| +157% | +$25.2K | ﹤0.01% | 8865 |
|
|
2018
Q4 | $16K | Buy |
+2,248
| New | +$18.8K | ﹤0.01% | 8822 |
|
|
2018
Q3 | – | Sell |
-2,767
| Closed | -$35K | – | 9781 |
|
|
2018
Q2 | $35K | Buy |
+2,767
| New | +$65.6K | ﹤0.01% | 8522 |
|
|
2018
Q1 | – | Sell |
-917
| Closed | -$45K | – | 8877 |
|
|
2017
Q4 | $45K | Buy |
+917
| New | +$56.4K | ﹤0.01% | 7663 |
|
|
2016
Q1 | – | Sell |
-1,421
| Closed | -$195K | – | 8137 |
|
|
2015
Q4 | $195K | Buy |
+1,421
| New | +$202K | ﹤0.01% | 5840 |
|
Other funds holding ATYR
GCP
KCM
Citadel Advisors's ATYR Position: Q2 2026 in Review
Citadel Advisors increased its aTyr Pharma (ATYR) stake by 2,522% in Q2 2026, buying an estimated $780K and bringing the position to 1,242,067 shares worth $741K. The position accounts for ﹤0.01% of the portfolio, ranked #8927.
Citadel Advisors first reported a position in ATYR in Q4 2015 and has held it in 26 quarters since. The position peaked at $3.71M in Q1 2024. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.
- Citadel Advisors held 1,242,067 shares of aTyr Pharma worth $741K as of Q2 2026.
- Citadel Advisors bought 1,194,695 aTyr Pharma shares in Q2 2026, an estimated $780K.
- aTyr Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8927 holding.
- Citadel Advisors first reported a position in aTyr Pharma in Q4 2015 and has held it in 26 quarters since.
- Citadel Advisors's aTyr Pharma position peaked at $3.71M in Q1 2024.
- 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.